Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2017, robust 3.6 percent annual growth in the non-Hodgkin's lymphoma drug market will be driven by increasing market penetration of Biogen Idec/Genentech/Chugai/Zenyaku Kogyo's Rituxan/Roche's MabThera, particularly in the chronic lymphocytic leukemia market.

The new Pharmacor report entitled Non-Hodgkin's Lymphoma finds that the development of therapies for the treatment of non-Hodgkin's lymphoma remains highly challenging because of the dominance Rituxan/MabThera holds across the subpopulations of the disease in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The report finds that Rituxan/MabThera will continue to dominate the non-Hodgkin's lymphoma market as interviewed thought leaders say they are satisfied with the drug's safety and efficacy and they do not expect to significantly utilize any late-stage emerging agents over the next decade.

Although sales of GlaxoSmithKline/Genmab's ofatumumab will grow at an impressive annual rate of 8.4 percent from 2012 to 2017 following its expected launch in 2009, it will not take significant patient share away from Rituxan/MabThera. Interviewed thought leaders do not expect ofatumumab to offer significant efficacy or tolerability advantages over Rituxan/MabThera.

"Rituxan/MabThera will continue to dominate the non-Hodgkin's lymphoma market over the next decade, owing to its widespread use in combination chemotherapy regimens in all non-Hodgkin's lymphoma patient segments, and it will retain its dominance despite the expected market entry of biosimilars," said Andrew Merron, Ph.D., analyst at Decision Resources. "Efficacious and tolerable emerging therapies will struggle to compete with Rituxan/MabThera and will likely enjoy greatest success if used in combination with Rituxan/MabThera."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Decision Resources                               Decision Resources, Inc.   Christopher Comfort                              Elizabeth Marshall   781-296-2597                                     781-296-2563   ccomfort@dresources.com                          emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Christopher Comfort of Decision Resources, +1-781-296-2597,
ccomfort@dresources.com or Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Medicaid Managed Care Program in Ohio Continues to Face Challenges

View Now